| Document |
Document Title |
|
WO/2019/114674A1 |
The present application relates to a method for prepare a Cangrelor tetrasodium salt, comprising: using N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)sulfonyl]a
denosine as a raw material to undergo two steps of reaction to obtain a ...
|
|
WO/2019/113462A1 |
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as East...
|
|
WO/2019/110734A1 |
The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention fu...
|
|
WO/2019/112485A1 |
The invention relates to the field of molecular biology, biotechnology and molecular diagnostics. The invention can be used in the development and optimisation of PCR and RT-PCR systems used for detecting nucleic acids, inter alia, for d...
|
|
WO/2019/109560A1 |
Provided is a method for extracting adenosine triphosphate from an adenosine triphosphate solution. The method is executed by using a heterocyclic compound, and the heterocyclic compound is a compound represented by formula (1), or a ste...
|
|
WO/2019/110991A1 |
The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.
|
|
WO/2019/112567A1 |
This invention provides protease activity screening matrices that contain a solid support conjugated to a substrate moiety that can be specifically cleaved by a specific protease. The invention also provides methods for utilizing the pro...
|
|
WO/2019/105388A1 |
The present invention relates to a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing an A3 adenosine receptor agonist an...
|
|
WO/2019/105421A1 |
The present invention relates to a nucleoside analogue having the structure of the following formula, a method for preparing the nucleoside analogue, and an application of the nucleoside analogue in nucleic acid sequencing, etc.
|
|
WO/2019/108875A1 |
Provided herein are methods and compositions related to treating and/or preventing glaucoma in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pt...
|
|
WO/2019/108878A1 |
Provided herein are methods and compositions related to treating and/or preventing obesity and/or conditions associated with obesity in a subject by administering to the subject (e.g., orally administering to the subject) a composition c...
|
|
WO/2019/108873A1 |
Provided herein are methods and compositions related to treating and/or preventing multiple sclerosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside...
|
|
WO/2019/102034A1 |
The present invention provides for stable nucleotide reagents used for nucleic acid amplification by PCR and RT-PCR (Reverse Transcriptase-PCR) that comprises modified nucleoside triphosphates. The present invention also provides for met...
|
|
WO/2019/103050A1 |
Provided is a compound that, after administration into an organism, rapidly binds to blood albumin, persistently circulates systemically, and efficiently accumulates in tumor tissue and then releases an active drug. The compound exhibits...
|
|
WO/2019/097233A1 |
The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising s...
|
|
WO/2019/092546A1 |
The present invention relates to a process for the preparation of Cangrelor in salt form of formula (V) by preparation and subsequent hydrolysis of an intermediate of formula (IV). The process is characterised by the high yield and purit...
|
|
WO/2019/088179A1 |
Provided are: a nucleoside that is more suitable for practical use such as an RNA medicine or the like; and the use of the nucleoside. For this purpose, provided is a nucleoside derivative represented by formula (1) or (2) or a salt ther...
|
|
WO/2019/089417A1 |
Provided herein are methods and compositions related to treating and/or preventing cystic fibrosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside an...
|
|
WO/2019/080724A1 |
Disclosed are a nucleoside phosphate compound, a pharmaceutical composition comprising same, and a preparation method therefor and the use thereof. Such a compound can be successfully metabolized within liver cells, and can produce an ac...
|
|
WO/2019/079686A1 |
Provided herein are methods and compositions related to treating and/or preventing diseases or disorder associated with cytoplasmic accumulation of TDP-43 by administering to the subject (e.g., orally administering to the subject) a comp...
|
|
WO/2019/079656A1 |
The present disclosure provides method and products for the selective enrichment of one population of DNA in a mixed sample comprising multiple populations of DNA. In some embodiments, the mixed sample comprises one or more populations o...
|
|
WO/2019/076633A1 |
The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of u...
|
|
WO/2019/071474A1 |
The present invention relates to the field of nucleotide sequencing. Specifically, the invention relates to a modified nucleoside or nucleotide, wherein the 3'-OH of said modified nucleoside or said nucleotide is reversibly blocked, and ...
|
|
WO/2019/075045A1 |
The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
|
|
WO/2019/072005A1 |
The present invention relates to an azacitidine disaccharide impurity, a preparation method therefor and use thereof. A compound of formula III is obtained by reacting a compound represented by formula IV as a start raw material with a t...
|
|
WO/2019/069297A2 |
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...
|
|
WO/2019/060740A1 |
Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the...
|
|
WO/2019/060692A1 |
The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5
-carboxamide. The morphic form can be a stable hemihydra...
|
|
WO/2019/053696A1 |
Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat disea...
|
|
WO/2019/052359A1 |
The aim of the present invention is to provide a compound containing a diheterocyclic ribavirin analog, a stereoisomer, a prodrug, a pharmaceutically acceptable salt, a compound salt and/or a solvated compound with structural general for...
|
|
WO/2019/053609A1 |
The present invention describes W-position modified cytidine nucleotides of formula (I). Provided herein are methods of chemical synthesis of ΛΡ-modified cytidine nucleoside triphosphates and their applications as well as uses of the c...
|
|
WO/2019/053659A1 |
The present disclosure relates to compounds and compositions containing 5'-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.
|
|
WO/2019/053476A1 |
The present invention relates to a process for the preparation of floxuridine, said process comprising reacting a compound of Formula la with a compound of Formula lla in the presence of an acid Al to provide a compound of Formula Ilia i...
|
|
WO/2019/042888A1 |
Disclosed is the use of perfluorinated nucleic acids and perfluorinated peptides as compounds with excellent properties. Surprisingly, it has been shown that compounds of nucleic acids and peptides with short-chain perfluorocarbons havin...
|
|
WO/2019/043177A1 |
The present invention relates to 2'-spirothietane nucleosides, and the phosphates and the prodrugs thereof, and the pharmaceutically acceptable salts and solvates thereof, and the use of such compounds as a medicament, in particular in t...
|
|
WO/2019/040418A1 |
Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3',4-didehydroribose.
|
|
WO/2019/036225A1 |
Diaryl-azo derivatives are efficient fluorescence quenchers as well as nucleic acid duplex-stabilizing agents and are useful in oligonucleotide conjugates and probes. The oligonucleotide-quencher conjugates may be used in detection metho...
|
|
WO/2019/032859A1 |
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2019/032411A1 |
The invention provides potent anti-cancer methods and compositions that employ novel glycome compounds exemplified by glyco-benzaldehydes that disrupt anaerobic respiration and trigger apoptosis in cancer cells. Additionally, the inventi...
|
|
WO/2019/025600A1 |
The present invention relates to a hydrate of sofosbuvir, more precisely to a monohydrate of sofosbuvir, and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the sofosbuvir h...
|
|
WO/2019/027920A1 |
Crystalline and amorphous forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihyd
rofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate (GS-9131), the vanillate, phosphate and xinafoate salts as well as the phospha...
|
|
WO/2019/023748A1 |
The present invention relates to a method of increasing fertility, or reducing rate of decline in fertility, or restoring fertility, of a female subject, comprising administering to the subject an effective amount of an agent which eleva...
|
|
WO/2019/023459A1 |
The present invention is directed to compounds of the formulae I, II and III as shown below (I) (II) (III) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the inven...
|
|
WO/2019/022158A1 |
Provided are a compound represented by formula I that can be used in nucleic acid photoreaction techniques, and a photoreactive crosslinking agent comprising the compound.
|
|
WO/2019/012080A1 |
The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications. The compounds have formula (I) wherein B is a nucleoside base; and Fl is a fluorophore attached through...
|
|
WO/2019/012328A1 |
The present invention relates to combination therapies of a cytarabine conjugate and one or more anti-neoplastic agents for inhibiting cancer cell growth. In particular, the present invention relates to a conjugate of cytarabine and aspa...
|
|
WO/2018/041942A9 |
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...
|
|
WO/2019/005898A1 |
Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-c...
|
|
WO/2019/006455A1 |
Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar ...
|
|
WO/2019/005901A1 |
Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting ...
|
